Effect of Essential Phospholipids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial.

In remaining subgroups, CAP score reduction at 6 months showed a numerical trend favouring EPL versus placebo (Figure S2E ).

also in 708 other papers

The improvement was sustained at 9 months, though the difference did not reach statistical significance (Figure 4 ).

also in 61,332 other papers

3.3.2 Changes in Symptom Evaluation EPL treatment showed a trend toward greater improvement, though statistically non‐significant, in fatigue and asthenia versus placebo at 6 months, whereas changes in depression and abdominal pain were similar between the arms (Table S10 ).

also in 31,039 other papers